A simple skin test has been developed and trialled that is able to identify people with these diseases below is the Medscape article based on information published online on March 20 in JAMA
"A simple skin biopsy test is able to detect an abnormal form of alpha-synuclein with high accuracy in individuals with neurodegenerative disorders such as Parkinson's disease (PD).
Researchers are hopeful that the test — which identified phosphorylated alpha-synuclein (P-SYN) with 95.5% accuracy in the blinded, multicenter trial — will accelerate not just early identification of synucleinopathies but also drug development.
Synucleinopathies include PD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF)."
"Each year, there are nearly 200,000 people in the U.S. who face a diagnosis of Parkinson's disease, dementia with Lewy bodies, and related disorders," "study investigator Christopher Gibbons, MD, professor of neurology at Harvard Medical School in Boston, Massachusetts, said in a press release.
He explained that patients often experience delays in diagnosis or are misdiagnosed due to the complexity of synucleinopathies.
"With a simple, minimally invasive skin biopsy test, this blinded, multicenter study demonstrated how we can more objectively identify the underlying pathology of synucleinopathies and offer better diagnostic answers and care for patients."
Comments